GlassScriptPhysician profile
Mircea N Coca
NPI 1932463585
$3,637.10
in general payments reported to CMS, 2019-2025
16 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $358 · 2021: $652 · 2022: $801 · 2023: $637 · 2024: $462 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,359.76 | 2019-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $441.91 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $385.84 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $362.94 | 2020-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $219.97 | 2023-2025 | Izervay |
| Abbvie INC. | $187.02 | 2022-2025 | Ozurdex, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $166.96 | 2019-2021 | |
| Eyepoint US, INC. | $143.12 | 2022-2023 | |
| Genentech, INC. | $96.50 | 2023-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $79.75 | 2024-2025 | Iluvien, Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $57.18 | 2019-2021 | |
| Harrow Eye, LLC | $55.95 | 2025 | Triesence, Iheezo |
| Alcon Vision LLC | $27.74 | 2024 | Rocklatan |
| Allergan, INC. | $24.30 | 2022 | |
| Oyster Point Pharma, INC. | $16.34 | 2023 | Tyrvaya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $11.82 | 2024 | Clearpath, Streamline, Kahook Dual Blade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mircea Coca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.